

September 26, 2024
Nobelpharma Co., Ltd.

**Filing Appeal with Intellectual Property High Court
Related to Patent-infringement Lawsuit
on “NOBELZIN® tablets 25 mg/50 mg” for Wilson’s Disease and Hypozincemia**

Nobelpharma Co., Ltd. (Headquarters: 1-17-24, Shinkawa, Chuo-ku, Tokyo, Managing Director & CEO: Jin Shiomura) announces that the company has decided to appeal to the Intellectual Property High Court, which specializes in intellectual property cases, against the September 26, 2024 ruling by Tokyo District Court to dismiss the claim in the suit filed by the company on April 17, 2023 in opposition to the manufacturer of the generic products of NOBELZIN, Sawai Pharmaceutical Co., Ltd., in Tokyo District Court to seek an injunction against an act of infringement of the company’s patents (Patent Numbers 6716464 and 6768984).

NOBELZIN was approved in January 2008 and launched in April of that year for Wilson’s disease, which is an orphan disease with estimated patients of 2,000 – 3,000. In March 2017, it was further approved for the additional indication of hypozincemia.

Nobelpharma has been carrying out the company mission, “Contribute to society by providing critical but neglected pharmaceuticals and medical devices,” since the day of its establishment. The intellectual properties that protect the technologies and products of the company are essential assets to realize the said mission, and the company are determined to take strict actions against any acts to violate such assets.

[Contact for Inquiries]

Noboru Kudo, Head of Communications

Nobelpharma Co., Ltd.

1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033

Tel: 03-6670-3800